OrthoPediatrics (KIDS) to Announce Quarterly Earnings on Tuesday

OrthoPediatrics (NASDAQ:KIDS) is expected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect OrthoPediatrics to announce earnings of ($0.31) per share and revenue of $68.21 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. The firm had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Stock Performance

KIDS opened at $20.19 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. The stock has a market capitalization of $518.48 million, a price-to-earnings ratio of -12.02 and a beta of 0.98. The company has a fifty day moving average of $18.97 and a 200 day moving average of $17.79. OrthoPediatrics has a fifty-two week low of $14.42 and a fifty-two week high of $22.80.

Analysts Set New Price Targets

KIDS has been the subject of several research reports. Truist Financial increased their price objective on shares of OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Friday, July 17th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a research report on Friday, April 24th. Finally, BTIG Research reaffirmed a “buy” rating and set a $24.00 price target on shares of OrthoPediatrics in a research note on Friday, May 1st. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.78.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its stake in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares during the last quarter. Caption Management LLC bought a new position in OrthoPediatrics in the 3rd quarter valued at $54,000. BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the period. Finally, State of Wyoming increased its stake in OrthoPediatrics by 189.7% in the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares during the period. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.